{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:45:41Z","timestamp":1761126341594},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>Most B\u2010cell malignancies are incurable diseases and therefore warrant new therapeutic approaches. In a pilot study, we tested the feasibility and safety of combined immunotherapy consisting of adoptive transfer of autologous tumour\u2010specific T cells, low\u2010dose interleukin 2 (IL\u20102) and a cellular vaccine of CD40\u2010activated plasma cell leukaemia (PCL) cells in a patient who failed tandem repeat stem cell transplantation and idiotype vaccination. Autologous tumour\u2010specific T cells for adoptive T\u2010cell transfer were propagated <jats:italic>in vitro<\/jats:italic> by repetitive stimulation with autologous <jats:italic>ex vivo<\/jats:italic> CD40\u2010activated PCL cells. CD40\u2010activated PCL cells for vaccination were similarly generated <jats:italic>ex vivo<\/jats:italic> by co\u2010culture with CD40 ligand transfectants. Autologous T cells (5\u2003\u00d7\u200310<jats:sup>8<\/jats:sup> and 2\u00b75\u2003\u00d7\u200310<jats:sup>9<\/jats:sup> for two separate treatment cycles) generated <jats:italic>ex vivo<\/jats:italic> and cytotoxic against autologous tumours were infused and well tolerated by the patient. Fever and myalgias were closely related to IL\u20102 injections and no other adverse effects were observed. A temporary decrease of PCL cells in peripheral blood was seen after the first cycle of adoptive T\u2010cell therapy, tumour cell vaccination and low\u2010dose IL\u20102. Tumour progression was associated with tumour cells that (1) expressed a complex karyotype, (2) demonstrated loss of MHC class II, and (3) did not induce autologous tumour\u2010specific T\u2010cell lines <jats:italic>ex vivo<\/jats:italic>. We demonstrated the safety and feasibility in combining autologous tumour\u2010specific T\u2010cell therapy with low\u2010dose IL\u20102 and that clinical trials based on the use of CD40\u2010activated autologous tumour cell vaccines are warranted in patients with CD40\u2010activated autologous tumour cells, either as a vaccine or for <jats:italic>ex vivo<\/jats:italic> stimulation of autologous T cells.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02760.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:28:54Z","timestamp":1027679334000},"page":"455-460","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A pilot study of combined immunotherapy with autologous adoptive tumour\u2010specific T\u2010cell transfer, vaccination with CD40\u2010activated malignant B cells and interleukin 2"],"prefix":"10.1111","volume":"113","author":[{"given":"J. L.","family":"Schultze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H.","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V90.2.549","article-title":"Ex vivo generation of human anti\u2010pre\u2010B leukemia\u2010specific autologous cytolytic T cells","volume":"90","author":"Cardoso A.A.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1997.tb00982.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199807000-00004"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-551"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1472"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199703000-00006"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210223271705"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1997.tb00974.x"},{"key":"e_1_2_6_10_1","first-page":"488","article-title":"Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the \u2018CD40 system\u2019","volume":"10","author":"Planken E.V.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood.V96.4.1274","article-title":"B7\u20132\u2010positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumour immunotherapy","volume":"96","author":"Pope B.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.4.925"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.18.8200"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V89.10.3806","article-title":"Autologous tumour infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro","volume":"89","author":"Schultze J.L.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119822"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199811000-00011"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.694"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80066-7"},{"key":"e_1_2_6_19_1","first-page":"483","article-title":"Current approaches to the management of non\u2010Hodgkin's lymphoma","volume":"25","author":"Vose J.M.","year":"1998","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331603"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02760.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02760.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02760.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T21:37:58Z","timestamp":1697578678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02760.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02760.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02760.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}